Amneal Pharmaceuticals Market Sentiment

Market sentiment signals for Amneal Pharmaceuticals (AMRX): analyst consensus, short interest, options flow and insider activity.

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Aug 26, 2026	JP Morgan	Chris Schott—	+22.1%	$22	Reinstates	Overweight
Aug 3, 2026	UBS	Ashwani Verma—	+38.7%	$23 → $25	Maintained	Buy
Jul 15, 2026	UBS	Ashwani Verma—	+27.6%	$19 → $23	Maintained	Buy
May 20, 2026	Barclays	Glen Santangelo—	-11.2%	$15 → $16	Maintained	Overweight
Apr 17, 2026	UBS	Ashwani Verma—	+5.4%	$19	Initiate	Buy
Mar 2, 2026	Truist Securities	Les Sulewski—	-5.7%	$15 → $17	Maintained	Buy
Dec 9, 2025	Barclays	Glen Santangelo—	-16.8%	$15	Initiate	Overweight
Oct 31, 2025	Piper Sandler	David Amsellem—	-27.9%	$11 → $13	Maintained	Overweight
Sep 16, 2025	JP Morgan	Chris Schott—	-22.3%	$12 → $14	Maintained	Overweight
Mar 3, 2025	Barclays	Balaji Prasad—	-39.0%	$10 → $11	Maintained	Overweight
Feb 24, 2025	JP Morgan	Chris Schott—	-33.4%	$9 → $12	Upgrade	Neutral→Overweight
Nov 11, 2024	Piper Sandler	David Amsellem—	-39.0%	$9 → $11	Maintained	Overweight
Oct 2, 2024	Truist Securities	Les Sulewski—	-33.4%	$10 → $12	Maintained	Buy
Sep 6, 2024	JP Morgan	Chris Schott—	-50.1%	$9	Upgrade	Underweight→Neutral
Aug 13, 2024	Barclays	Balaji Prasad—	-44.5%	$8 → $10	Maintained	Overweight
Aug 12, 2024	Truist Securities	Les Sulewski—	-44.5%	$9 → $10	Maintained	Buy
May 6, 2024	Goldman Sachs	Nathan Rich—	-55.6%	$6 → $8	Maintained	Buy
May 6, 2024	Truist Securities	Les Sulewski—	-50.1%	$7 → $9	Maintained	Buy
Mar 21, 2024	Piper Sandler	David Amsellem—	-55.6%	$6 → $8	Maintained	Overweight
Mar 4, 2024	Goldman Sachs	Nathan Rich—	-65.3%	$6 → $6	Maintained	Buy
Jan 29, 2024	Barclays	Balaji Prasad—	-55.6%	$6 → $8	Maintained	Overweight
Nov 8, 2023	Truist Securities	Gregory Fraser—	-61.2%	$6 → $7	Maintained	Buy
Sep 6, 2023	Truist Securities	Gregory Fraser—	-66.7%	$6	Maintained	Buy